Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 116
Filtrar
1.
J Chromatogr Sci ; 59(6): 502-509, 2021 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-33884406

RESUMO

For the quantification of flurbiprofen in rat plasma, a simple UPLC-MS/MS method with high sensitivity and short retention time for flurbiprofen was developed and validated using specific parameters. Etodolac was used as internal standard. The transitions (precursor to the product) of flurbiprofen and internal standard were obtained using the electrospray ionization in the negative ion multiple reaction monitoring mode, 243.2 â†’ 199.2, 286.2 â†’ 212.1, respectively. For chromatographic separation, C18 column was used for the stationary phase and gradient elution was used for the mobile phase. This mobile phase consisted of a methanol (A) and a 5 mM ammonium formate solution (B), which varied at a flow rate of 0.4 mL/min. For flurbiprofen, LLOQ was determined as 5 ng/mL. Quantification of flurbiprofen in the rat plasma with a linear calibration curve of 5-5000 ng/mL (r > 0.9991 for plasma) is possible with a retention time of 1.89 min. The total analysis time of the method was 3 min. The proposed method was validated. The intraday and inter-day precision (RSD%) and accuracy (RE%) were within 10% in all cases for flurbiprofen. The stability of flurbiprofen was evaluated under conditions such as short-term, long-term, autosampler and freeze/thaw. After method validation, flurbiprofen was succesfully quantified in real rat plasma samples.


Assuntos
Anti-Inflamatórios não Esteroides/sangue , Cromatografia Líquida de Alta Pressão/métodos , Flurbiprofeno/sangue , Espectrometria de Massas em Tandem/métodos , Animais , Monitoramento de Medicamentos/métodos , Limite de Detecção , Masculino , Ratos , Ratos Wistar
2.
Talanta ; 207: 120284, 2020 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-31594616

RESUMO

Magnetic carbon nanotubes (CNTs) with encapsulated Co nanoparticles (Co@CNTs), was synthesized by exploiting the one-step pyrolysis strategy using ZIF-67 as template. The as-synthesized Co@CNTs is provided with the nanopores, a large specific surface area, and strong magnetic response. The obtained Co@CNTs was used as magnetic solid-phase extraction adsorbents to extract two profens including flurbiprofen and ketoprofen. The parameters of extraction efficiency, involving extraction time, sample solution volume, ionic strength, pH and the conditions of desorption efficiency, were optimized in detail. After determined by high-performance liquid chromatography-ultraviolet (HPLC-UV), the results evinced that Co@CNTs showed a high extraction efficiency with high enrichment factors of 832 and 672. The good linear range of both flurbiprofen and ketoprofen were all 5.0-1000 ng L-1, with the limit of detection were 0.60 ng L-1 and 0.70 ng L-1, respectively. Furthermore, a valid method for the extraction of flurbiprofen and ketoprofen from human serum was established. The spiking recoveries of two profens were between 86.74% and 97.22%, and the relative standard deviation was less than 6.55%. Co@CNTs can be repeatedly used at least 10 times, indicating its excellent regeneration and reusability. The results demonstrated that the Co@CNTs materials exhibits high enrichment ability and extraction efficiency, playing great promise in MSPE.


Assuntos
Flurbiprofeno/isolamento & purificação , Cetoprofeno/isolamento & purificação , Imãs/química , Nanotubos de Carbono/química , Compostos Organometálicos/química , Extração em Fase Sólida/métodos , Adsorção , Cobalto/química , Flurbiprofeno/sangue , Flurbiprofeno/química , Humanos , Imidazóis/química , Cetoprofeno/sangue , Cetoprofeno/química , Nanopartículas Metálicas/química
3.
Anal Chim Acta ; 1009: 56-64, 2018 Jun 07.
Artigo em Inglês | MEDLINE | ID: mdl-29422132

RESUMO

In this paper, parallel artificial liquid membrane extraction (PALME) was used for the first time to clean-up dried blood spots (DBS) prior to ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Fundamental studies exploring amongst others desorption from the DBS in alkaline or acidic aqueous conditions, total extraction time and absolute recoveries were executed. Desorption and PALME were performed using a set of two 96-well plates, one of them housing the sample and the other comprising the supported liquid membrane (SLM) and the acceptor solution. In one procedure, amitriptyline and quetiapine (basic model analytes) were desorbed from the DBS using 250 µL of 10 mM sodium hydroxide solution (aqueous), and subsequently extracted through the SLM consisting of 4 µL of 1% trioctylamine in dodecyl acetate, and further into an acceptor solution consisting of 50 µL of 20 mM formic acid. In a second procedure, ketoprofen, fenoprofen, flurbiprofen, and ibuprofen (acidic model analytes) were desorbed from the DBS into 20 mM formic acid, extracted through an SLM with dihexyl ether, and further into an acceptor solution of 25 mM ammonia. Within 60 min of PALME, both basic and acidic model analytes were effectively desorbed from the DBS and extracted into the acceptor solution, which was injected directly into the analytical instrument. Recoveries between 63 and 85% for the six model analytes were obtained. PALME provided excellent clean-up from the DBS samples, and acceptor solutions were free from phospholipids. Linearity was obtained with r2 > 0.99 for five of the six analytes. Accuracy, precision and UHPLC-MS/MS matrix effects were in accordance with the European Medicines Agency (EMA) guideline. Based on these experiments, PALME shows great potential for future processing of DBS in a short and simple way, and with the presented setup, up to 96 DBS can be processed within a total extraction time of 60 min.


Assuntos
Teste em Amostras de Sangue Seco , Extração Líquido-Líquido , Amitriptilina/sangue , Cromatografia Líquida de Alta Pressão , Fenoprofeno/sangue , Flurbiprofeno/sangue , Voluntários Saudáveis , Humanos , Ibuprofeno/sangue , Cetoprofeno/sangue , Membranas Artificiais , Fumarato de Quetiapina/sangue , Espectrometria de Massas em Tandem
4.
Eur J Pharm Sci ; 92: 224-34, 2016 Sep 20.
Artigo em Inglês | MEDLINE | ID: mdl-27185298

RESUMO

Poor brain penetration of tarenflurbil (TFB) was one of the major reasons for its failure in phase III clinical trials conducted on Alzheimer's patients. Thus there is a tremendous need of developing efficient delivery systems for TFB. This study was designed with the aim of improving drug delivery to brain through intranasally delivered nanocarriers. TFB was loaded into two different nanocarriers i.e., poly (lactide-co-glycolide) nanoparticles (TFB-NPs) and solid lipid nanoparticles (TFB-SLNs). Particle size of both the nanocarriers (<200nm) as determined by dynamic light scattering technique and transmission electron microscopy, assured transcellular transport across olfactory axons whose diameter was ≈200nm and then paving a direct path to brain. TFB-NPs and TFB-SLNs resulted in 64.11±2.21% and 57.81±5.32% entrapment efficiencies respectively which again asserted protection of drug from chemical and biological degradation in nasal cavity. In vitro release studies proved the sustained release of TFB from TFB-NPs and TFB-SLNs in comparison with pure drug, indicating prolonged residence times of drug at targeting site. Pharmacokinetics suggested improved circulation behavior of nanoparticles and the absolute bioavailabilities followed this order: TFB-NPs (i.n.)>TFB-SLNs (i.n.)>TFB solution (i.n.)>TFB suspension (oral). Brain targeting efficiency was determined in terms of %drug targeting efficiency (%DTE) and drug transport percentage (DTP). The higher %DTE (287.24) and DTP (65.18) were observed for TFB-NPs followed by TFB-SLNs (%DTE: 183.15 and DTP: 45.41) among all other tested groups. These encouraging results proved that therapeutic concentrations of TFB could be transported directly to brain via olfactory pathway after intranasal administration of polymeric and lipidic nanoparticles.


Assuntos
Encéfalo/metabolismo , Portadores de Fármacos/administração & dosagem , Flurbiprofeno/administração & dosagem , Flurbiprofeno/farmacocinética , Nanopartículas/administração & dosagem , Administração Intranasal , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/metabolismo , Animais , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Flurbiprofeno/sangue , Flurbiprofeno/química , Ácido Láctico/química , Lipídeos/química , Fígado/metabolismo , Pulmão/metabolismo , Masculino , Miocárdio/metabolismo , Nanopartículas/química , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Ratos Sprague-Dawley , Baço/metabolismo
5.
Eur J Clin Pharmacol ; 72(1): 53-9, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26438533

RESUMO

PURPOSE: The purpose of this study is to investigate the pharmacokinetics and deep tissue penetration capability of the newly developed S-flurbiprofen plaster (SFPP) in humans. METHODS: Study 1: SFPP tape-type patch (2-60 mg) was applied to the lower back for 24 h in healthy adult volunteers. S-flurbiprofen (SFP) plasma concentration was measured over time to examine SFP pharmacokinetics. Study 2: SFPP (20 mg) was applied for 12 h to the affected knee of osteoarthritis (OA) patients who were scheduled for total knee arthroplasty. Deep tissues (synovial tissue and synovial fluid) were collected during surgery to compare SFP concentrations after application of SFPP or a commercially available flurbiprofen (FP) gel-type patch. RESULTS: Study 1: The plasma concentration of SFP was sustained during 24-h topical application of the SFPP, showing a high percutaneous absorption ratio of 51.4-72.2 %. Cmax and AUC0-∞ were dose-proportional. Study 2: After application of the SFPP for 12 h, SFP concentrations in the synovial tissue and synovial fluid were 14.8-fold (p = 0.002) and 32.7-fold (p < 0.001) higher, respectively, than those achieved by the FP patch. CONCLUSIONS: Sustained plasma concentration of SFP and high percutaneous absorption ratio was observed after 24-h topical application of the SFPP. Compared to the FP patch, the SFPP showed superior percutaneous absorption and greater tissue penetration of SFP into the synovial tissue. Greater tissue penetration of the SFPP seemed to be primarily due to its formulation. Thus, SFPP is expected to show higher efficacy for the treatment of knee OA.


Assuntos
Anti-Inflamatórios não Esteroides/sangue , Anti-Inflamatórios não Esteroides/farmacocinética , Flurbiprofeno/sangue , Flurbiprofeno/farmacocinética , Osteoartrite do Joelho/metabolismo , Membrana Sinovial/metabolismo , Administração Tópica , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Inflamatórios não Esteroides/administração & dosagem , Feminino , Flurbiprofeno/administração & dosagem , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Osteoartrite do Joelho/sangue , Método Simples-Cego , Adesivo Transdérmico , Adulto Jovem
6.
Vet Ophthalmol ; 19 Suppl 1: 24-9, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26119523

RESUMO

OBJECTIVE: To investigate systemic absorption and renal effects of topically applied ophthalmic flurbiprofen and diclofenac in healthy cats. ANIMALS STUDIED: Twelve domestic shorthair cats. PROCEDURES: Cats were randomly assigned to two treatment groups (n = 6) and administered one drop (approximately 40 µL) of either flurbiprofen 0.03% or diclofenac 0.1% in both eyes four times daily (6 am, 12 pm, 6 pm, and 12 am) for 14 days. Blood samples were collected on days 0, 4, 8, 14, 16, and 17 and analyzed by liquid chromatography and mass spectrometry for flurbiprofen and diclofenac plasma concentrations. A complete blood count (CBC), serum chemistry, and urinalysis were analyzed at the beginning of the study (Day 0) and at the end of topical drug administration (Day 15). RESULTS: Both drugs demonstrated systemic absorption. Flurbiprofen was detected (mean ± SD) at day 4 (237 ± 65 ng/mL), day 8 (396 ± 91 ng/mL), day 14 (423 ± 56 ng/mL), day 16 (350 ± 66 ng/mL), and day 17 (270 ± 62 ng/mL), and diclofenac was detected (mean ± SD) at day 4 (130 ± 44 ng/mL), day 8 (131 ± 25 ng/mL), day 14 (150 ± 36 ng/mL), and sporadically on day 16 [corrected]. Flurbiprofen plasma concentration decreased slowly over 48 h after the last dose. No clinically significant abnormalities were noted in the serum blood urea nitrogen, creatinine, or urine specific gravity at the end of topical drug administration compared to the beginning of the study. CONCLUSIONS: Flurbiprofen and diclofenac were systemically absorbed after topical administration four times daily to both eyes of healthy cats. Flurbiprofen reached higher plasma concentrations compared to diclofenac.


Assuntos
Inibidores de Ciclo-Oxigenase/farmacocinética , Diclofenaco/farmacocinética , Olho/efeitos dos fármacos , Flurbiprofeno/farmacocinética , Soluções Oftálmicas/farmacocinética , Absorção Fisiológica , Administração Oftálmica , Animais , Gatos , Inibidores de Ciclo-Oxigenase/farmacologia , Diclofenaco/sangue , Diclofenaco/farmacologia , Olho/metabolismo , Feminino , Flurbiprofeno/sangue , Flurbiprofeno/farmacologia , Masculino , Soluções Oftálmicas/farmacologia
7.
Eur J Pharm Biopharm ; 94: 64-72, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25979136

RESUMO

The purpose of this study was to develop novel solid lipid nanoparticle (SLN)-loaded dual-reverse thermosensitive hydrogel (DRTH) for rectal administration of flurbiprofen with improved bioavailability and reduced initial burst effect. The flurbiprofen-loaded SLNs were prepared by hot homogenisation technique, after optimising the amounts of lipid mixture (tricaprin and triethanolamine in 8:2 weight ratio), drug and surfactant. The flurbiprofen-loaded thermosensitive SLN composed of drug, lipid mixture and surfactant at a weight ratio of 10/15/1.3 was a solid at room temperature, and changed to liquid form at physiological temperature due to its melting point of about 32°C. This SLN gave the mean particle size of about 190nm and entrapment efficiency of around 90%. The DRTHs were prepared by adding this flurbiprofen-loaded thermosensitive SLN in various poloxamer solutions. Their rheological characterisation, release and stability were investigated while a morphological and pharmacokinetic study was performed after its rectal administration to rats compared with the drug and hydrogel. Poloxamer 188 and SLN decreased the gelation temperature and gelation time, but increased the viscosity at 25°C, gel strength and mucoadhesive force of DRTHs. In particular, the DRTH composed of [SLN/P 407/P 188 (10%/15%/25%)] with the gelation temperature of about 35°C existed as liquid at room temperature, but gelled at 30-36°C, leading to opposite reversible property of SLN. Thus, it was easy to administer rectally, and it gelled rapidly inside the body. This DRTH gave a significantly increased dissolution rate of the drug as compared to the flurbiprofen, but significantly retarded as compared to the hydrogel, including the initial dissolution rate. Moreover, this DRTH gave significantly higher plasma concentration and 7.5-fold AUC values compared to the drug, and lower initial plasma concentration and Cmax value compared to the hydrogel due to reduced initial burst effect. No damage in rectal mucosa was observed after the application of DRTH. Thus, this DRTH system with improved bioavailability and reduced initial burst effect would be recommended as an alternative for the flurbiprofen-loaded rectal pharmaceutical products.


Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Portadores de Fármacos , Etanolaminas/química , Flurbiprofeno/administração & dosagem , Temperatura Alta , Nanopartículas , Triglicerídeos/química , Adesividade , Administração Retal , Animais , Anti-Inflamatórios não Esteroides/sangue , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacocinética , Área Sob a Curva , Disponibilidade Biológica , Química Farmacêutica , Flurbiprofeno/sangue , Flurbiprofeno/química , Flurbiprofeno/farmacocinética , Hidrogéis , Masculino , Nanomedicina , Tamanho da Partícula , Poloxâmero/química , Ratos Sprague-Dawley , Reologia , Solubilidade , Tensoativos/química , Tecnologia Farmacêutica/métodos , Viscosidade
8.
Artigo em Inglês | MEDLINE | ID: mdl-25988430

RESUMO

A simple, quick and accurate LC-MS/MS method for the quantification of flurbiprofen in human plasma with indomethacin as internal standard (IS) was developed and validated. Samples were treated with methanol to precipitate proteins, then separated on a Ultimate C18 column (5µm, 2.1×50mm) with a gradient elusion process. Mobile phase A was comprised of water and formic acid, mobile phase B was comprised of acetonitrile and formic acid. Multi reaction monitoring (MRM) signals were saved on a negative ionization electrospray mass spectrometer. The calibration curve showed good linearity in the range of 40.00-10000.00µg/L (r(2)=0.998). Intra-day RE was 0.2-2.2%. Inter-day RE was 0.5-3.4%. The samples showed good stability under the study conditions. No significant matrix effect was observed. The established method was then applied to a bioequivalence study of a flurbiprofen axetil formulation.


Assuntos
Anti-Inflamatórios não Esteroides/sangue , Cromatografia Líquida de Alta Pressão/métodos , Flurbiprofeno/sangue , Espectrometria de Massas em Tandem/métodos , Adulto , Anti-Inflamatórios não Esteroides/farmacocinética , Flurbiprofeno/farmacocinética , Humanos , Masculino , Equivalência Terapêutica
9.
J Chromatogr Sci ; 53(9): 1443-8, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25820260

RESUMO

A simple high-performance liquid chromatography method has been developed for determination of flurbiprofen in human plasma. The method was validated on an Ace C18 column using UV detection. The mobile phase was acetonitrile-0.05 M potassium dihydrogen phosphate solution (60:40, v/v) adjusted to pH 3.5 with phosphoric acid. The calibration curve was linear between the concentration range of 0.10-5.0 µg/mL. Intra- and inter-day precision values for flurbiprofen in plasma were <4.47, and accuracy (relative error) was better than 3.67%. The extraction recoveries of flurbiprofen from human plasma were between 93.0 and 98.9%. The limits of detection and quantification of flurbiprofen were 0.03 and 0.10 µg/mL, respectively. In addition, this assay was applied to determine the pharmacokinetic parameters of flurbiprofen in six healthy Turkish volunteers who had been given 100 mg flurbiprofen.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Flurbiprofeno/sangue , Flurbiprofeno/química , Humanos , Limite de Detecção , Modelos Lineares , Masculino , Reprodutibilidade dos Testes
10.
Pharmacology ; 94(3-4): 143-7, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25277061

RESUMO

Flurbiprofen is a nonsteroidal anti-inflammatory agent preferentially used for local oromucosal treatment of painful and/or inflammatory conditions of the oropharynx such as gingivitis, stomatitis, periodontitis, pharyngitis and laryngitis. In this study, we have investigated the bioavailability of a new generic formulation of flurbiprofen lozenges developed by Epifarma Srl, compared to the originator Benactiv Gola® taken as reference. Within the framework of a formal bioequivalence study, we investigated in particular the putative influence of oral dissolution time (i.e. the time spent suckling the lozenge from its intake to complete dissolution) on the absorption rate, and the contribution of this factor to the total variability of plasma flurbiprofen during absorption. We found that the amount of flurbiprofen absorbed into the systemic circulation is not significantly higher for the test drug compared to that of the reference product. We observed that the length of oral dissolution time is inversely correlated to 10-min flurbiprofen plasma levels in the test but not in the reference formulation. We estimated that oral dissolution time accounts for about 14% of overall variability in flurbiprofen plasma 10 min after test drug administration.


Assuntos
Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacocinética , Flurbiprofeno/química , Flurbiprofeno/farmacocinética , Administração Oral , Adulto , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/sangue , Estudos Cross-Over , Feminino , Flurbiprofeno/administração & dosagem , Flurbiprofeno/sangue , Humanos , Absorção Intestinal , Masculino , Solubilidade , Comprimidos , Adulto Jovem
11.
Artigo em Inglês | MEDLINE | ID: mdl-25264913

RESUMO

Flurbiprofen (FLB) is one of the phenylalkanoic acid derivatives of non-steroidal anti-inflammatory drugs used for the management of pain and inflammation in patients with arthritis. We developed and validated a rapid and sensitive high-performance liquid chromatography analytical method utilizing tandem mass spectrometry (HPLC-MS/MS) for the simultaneous determination of FLB and its major metabolite, 4'-hydroxyflurbiprofen (4'-OH-FLB), in human plasma. Probenecid was used as an internal standard (IS). After liquid-liquid extraction with methyl t-butyl ether, chromatographic separation of the two analytes was achieved using a reversed-phase Luna C18 column (2.0mm×50mm, 5µm particles) with a mobile phase of 10mM ammonium formate buffer (pH 3.5)-methanol (15:85, v/v) and quantified by MS/MS detection in ESI negative ion mode. The flow rate of the mobile phase was 250µl/min and the retention times of FLB, 4'-OH-FLB, and IS were 1.1, 0.8, and 0.9min, respectively. The calibration curves were linear over a range of 0.01-10µg/ml for FLB and 0.01-1µg/ml for 4'-OH-FLB. The lower limit of quantifications using 100µl of human plasma was 0.01µg/ml for both analytes. The mean accuracy and precision for intra- and inter-run validation of FLB and 4'-OH-FLB were all within acceptable limits. The present HPLC-MS/MS method showed improved sensitivity for quantification of the FLB and its major metabolite in human plasma compared with previously described analytical methods. The validated method was successfully applied to a pharmacokinetic study in humans.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Flurbiprofeno/análogos & derivados , Flurbiprofeno/sangue , Espectrometria de Massas em Tandem/métodos , Anti-Inflamatórios não Esteroides , Artrite/tratamento farmacológico , Flurbiprofeno/farmacocinética , Humanos , Masculino , Controle de Qualidade , Reprodutibilidade dos Testes , República da Coreia , Sensibilidade e Especificidade , Espectrometria de Massas por Ionização por Electrospray
12.
J AOAC Int ; 97(4): 1061-6, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25145138

RESUMO

This paper describes a GCIMS method for the determination of flurbiprofen in human plasma. Flurbiprofen and internal standard ibuprofen were extracted from plasma by using a liquid-liquid extraction method. Derivatization was carried out using N-Methyl-N-(trimethylsilyl)trifluoroacetamide. The calibration curve was linear between the concentration range of 0.10 and 5.0 microg/mL. Intraday and interday precision values for flurbiprofen in plasma were less than 5.49%, and accuracy (relative error) was better than 5.33%. The extraction recoveries of flurbiprofen from human plasma were between 93.6 and 98.6%. The LOD and LOQ of flurbiprofen were 0.03 and 0.10 microg/mL, respectively. This assay was applied to determine the pharmacokinetic parameters of flurbiprofen in healthy Turkish volunteers who had been given 100 mg of flurbiprofen.


Assuntos
Flurbiprofeno/sangue , Flurbiprofeno/farmacocinética , Cromatografia Gasosa-Espectrometria de Massas , Humanos
13.
Clin Pharmacol Ther ; 96(3): 349-59, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24722393

RESUMO

The suitability of the capillary dried blood spot (DBS) sampling method was assessed for simultaneous phenotyping of cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) using a cocktail approach. Ten volunteers received an oral cocktail capsule containing low doses of the probes bupropion (CYP2B6), flurbiprofen (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), midazolam (CYP3A), and fexofenadine (P-gp) with coffee/Coke (CYP1A2) on four occasions. They received the cocktail alone (session 1), and with the CYP inhibitors fluvoxamine and voriconazole (session 2) and quinidine (session 3). In session 4, subjects received the cocktail after a 7-day pretreatment with the inducer rifampicin. The concentrations of probes/metabolites were determined in DBS and plasma using a single liquid chromatography-tandem mass spectrometry method. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. Important modulation of CYP and P-gp activities was observed in the presence of inhibitors and the inducer. Minimally invasive one- and three-point (at 2, 3, and 6 h) DBS-sampling methods were found to reliably reflect CYP and P-gp activities at each session.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/sangue , Sistema Enzimático do Citocromo P-450/sangue , Teste em Amostras de Sangue Seco , Preparações Farmacêuticas/sangue , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Administração Oral , Adulto , Bupropiona/administração & dosagem , Bupropiona/sangue , Bupropiona/farmacocinética , Cafeína/administração & dosagem , Cafeína/sangue , Cafeína/farmacocinética , Cápsulas , Bebidas Gaseificadas , Cromatografia Líquida de Alta Pressão , Cromatografia de Fase Reversa , Café , Inibidores das Enzimas do Citocromo P-450 , Dextrometorfano/administração & dosagem , Dextrometorfano/sangue , Dextrometorfano/farmacocinética , Inibidores Enzimáticos/administração & dosagem , Estudos de Viabilidade , Flurbiprofeno/administração & dosagem , Flurbiprofeno/sangue , Flurbiprofeno/farmacocinética , Humanos , Isoenzimas , Masculino , Midazolam/administração & dosagem , Midazolam/sangue , Midazolam/farmacocinética , Omeprazol/administração & dosagem , Omeprazol/sangue , Omeprazol/farmacocinética , Preparações Farmacêuticas/administração & dosagem , Fenótipo , Projetos Piloto , Valor Preditivo dos Testes , Espectrometria de Massas por Ionização por Electrospray , Especificidade por Substrato , Espectrometria de Massas em Tandem , Terfenadina/administração & dosagem , Terfenadina/análogos & derivados , Terfenadina/sangue , Terfenadina/farmacocinética , Adulto Jovem
14.
Bioanalysis ; 6(2): 151-64, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24423593

RESUMO

BACKGROUND: An LC-MS/MS method has been developed for the simultaneous quantification of P-glycoprotein (P-gp) and cytochrome P450 (CYP) probe substrates and their Phase I metabolites in DBS and plasma. P-gp (fexofenadine) and CYP-specific substrates (caffeine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, omeprazole for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4) and their metabolites were extracted from DBS (10 µl) using methanol. Analytes were separated on a reversed-phase LC column followed by SRM detection within a 6 min run time. RESULTS: The method was fully validated over the expected clinical concentration range for all substances tested, in both DBS and plasma. The method has been successfully applied to a PK study where healthy male volunteers received a low dose cocktail of the here described P-gp and CYP probes. Good correlation was observed between capillary DBS and venous plasma drug concentrations. CONCLUSION: Due to its low-invasiveness, simple sample collection and minimal sample preparation, DBS represents a suitable method to simultaneously monitor in vivo activities of P-gp and CYP.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Cromatografia Líquida de Alta Pressão , Sistema Enzimático do Citocromo P-450/metabolismo , Preparações Farmacêuticas/sangue , Espectrometria de Massas em Tandem , Animais , Bupropiona/sangue , Bupropiona/metabolismo , Bupropiona/farmacocinética , Cafeína/sangue , Cafeína/metabolismo , Cafeína/farmacocinética , Calibragem , Cromatografia Líquida de Alta Pressão/normas , Dextrometorfano/sangue , Dextrometorfano/metabolismo , Dextrometorfano/farmacocinética , Teste em Amostras de Sangue Seco , Flurbiprofeno/sangue , Flurbiprofeno/metabolismo , Flurbiprofeno/farmacocinética , Meia-Vida , Masculino , Midazolam/sangue , Midazolam/metabolismo , Midazolam/farmacocinética , Omeprazol/sangue , Omeprazol/metabolismo , Omeprazol/farmacocinética , Preparações Farmacêuticas/metabolismo , Especificidade por Substrato , Espectrometria de Massas em Tandem/normas , Terfenadina/análogos & derivados , Terfenadina/sangue , Terfenadina/metabolismo , Terfenadina/farmacocinética
15.
Int J Nanomedicine ; 8: 4147-55, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24204143

RESUMO

This study aimed to develop an oral delivery system using clay-based organic-inorganic hybrid materials to improve the bioavailability of the drug, flurbiprofen, which is poorly soluble in water. 3-aminopropyl functionalized magnesium phyllosilicate (AMP clay) was synthesized by a one-pot direct sol-gel method, and then flurbiprofen (FB) was incorporated into AMP clay (FB-AMP) at different drug/clay ratios. The structural characteristics of AMP and FB-AMP formulation were confirmed by X-ray diffraction, Fourier transform infrared spectroscopy, and transmission electron microscopy. Among tested formulations, FB-AMP(3), dramatically increased the dissolution of FB and achieved rapid and complete drug release within 2 hours. More than 60% of FB was released from FB-AMP(3) after 30 minutes; the drug was completely dissolved in the water within 2 hours. Under the acidic condition (pH 1.2), FB-AMP(3) also increased the dissolution of FB by up to 47.1% within 1 hour, which was three-fold higher than that of untreated FB. Furthermore, following an oral administration of FB-AMP(3) to Sprague-Dawley rats, the peak plasma concentration and area under the plasma concentration-time curve of FB increased two-fold, and the time to reach the peak plasma concentration was shortened compared with that in the untreated FB. This result suggests that the oral drug delivery system using clay-based organic-inorganic hybrid material might be useful to improve the bioavailability of FB.


Assuntos
Portadores de Fármacos/química , Flurbiprofeno/química , Flurbiprofeno/farmacocinética , Silicatos de Magnésio/química , Administração Oral , Animais , Disponibilidade Biológica , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/farmacocinética , Flurbiprofeno/administração & dosagem , Flurbiprofeno/sangue , Concentração de Íons de Hidrogênio , Silicatos de Magnésio/administração & dosagem , Silicatos de Magnésio/farmacocinética , Masculino , Ratos , Ratos Sprague-Dawley , Solubilidade
16.
Biomed Res Int ; 2013: 287919, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24260738

RESUMO

The rationale of the present study is to formulate flurbiprofen colon targeted compression coated tablets using guar gum to improve the therapeutic efficacy by increasing drug levels in colon, and also to reduce the side effects in upper gastrointestinal tract. Direct compression method was used to prepare flurbiprofen core tablets, and they were compression coated with guar gum. Then the tablets were optimized with the support of in vitro dissolution studies, and further it was proved by pharmacokinetic studies. The optimized formulation (F4) showed almost complete drug release in the colon (99.86%) within 24 h without drug loss in the initial lag period of 5 h (only 6.84% drug release was observed during this period). The pharmacokinetic estimations proved the capability of guar gum compression coated tablets to achieve colon targeting. The C(max) of colon targeted tablets was 11956.15 ng/mL at T max of 10 h whereas it was 15677.52 ng/mL at 3 h in case of immediate release tablets. The area under the curve for the immediate release and compression coated tablets was 40385.78 and 78214.50 ng-h/mL and the mean resident time was 3.49 and 10.78 h, respectively. In conclusion, formulation of guar gum compression coated tablets was appropriate for colon targeting of flurbiprofen.


Assuntos
Química Farmacêutica/métodos , Colo/efeitos dos fármacos , Flurbiprofeno/farmacologia , Flurbiprofeno/farmacocinética , Galactanos/química , Mananas/química , Gomas Vegetais/química , Estabilidade de Medicamentos , Flurbiprofeno/sangue , Voluntários Saudáveis , Humanos , Cinética , Comprimidos com Revestimento Entérico/farmacocinética , Comprimidos com Revestimento Entérico/farmacologia , Fatores de Tempo
17.
Neuropharmacology ; 71: 204-15, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23597506

RESUMO

Damaging of peripheral nerves may result in chronic neuropathic pain for which the likelihood is increased in the elderly. We assessed in mice if age-dependent alterations of endocannabinoids contributed to the heightened vulnerability to neuropathic pain at old age. We assessed nociception, endocannabinoids and the therapeutic efficacy of R-flurbiprofen in young and aged mice in the spared nerve injury model of neuropathic pain. R-flurbiprofen was used because it is able to reduce neuropathic pain in young mice in part by increasing anandamide. Aged mice developed stronger nociceptive hypersensitivity after sciatic nerve injury than young mice. This was associated with low anandamide levels in the dorsal root ganglia, spinal cord, thalamus and cortex, which further decreased after nerve injury. In aged mice, R-flurbiprofen had only weak antinociceptive efficacy and it failed to restore normal anandamide levels after nerve injury. In terms of the mechanisms, we found that fatty acid amide hydrolase (FAAH) which degrades anandamide, was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences. However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide. This may overwhelm the capacity of R-flurbiprofen to restore anandamide homeostasis and may contribute to the heightened risk for neuropathic pain at old age.


Assuntos
Envelhecimento , Ácidos Araquidônicos/deficiência , Modelos Animais de Doenças , Endocanabinoides/deficiência , Neuralgia/etiologia , Nervos Periféricos/metabolismo , Amidoidrolases/biossíntese , Amidoidrolases/metabolismo , Animais , Ácidos Araquidônicos/metabolismo , Comportamento Animal/efeitos dos fármacos , Encéfalo/efeitos dos fármacos , Encéfalo/crescimento & desenvolvimento , Encéfalo/metabolismo , Ciclo-Oxigenase 1/biossíntese , Ciclo-Oxigenase 1/metabolismo , Inibidores de Ciclo-Oxigenase/sangue , Inibidores de Ciclo-Oxigenase/farmacocinética , Inibidores de Ciclo-Oxigenase/uso terapêutico , Citocromo P-450 CYP2D6/biossíntese , Citocromo P-450 CYP2D6/metabolismo , Endocanabinoides/metabolismo , Indução Enzimática , Flurbiprofeno/sangue , Flurbiprofeno/farmacocinética , Flurbiprofeno/uso terapêutico , Masculino , Proteínas de Membrana/biossíntese , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Proteínas do Tecido Nervoso/biossíntese , Proteínas do Tecido Nervoso/metabolismo , Neuralgia/sangue , Neuralgia/tratamento farmacológico , Neuralgia/metabolismo , Nervos Periféricos/efeitos dos fármacos , Nervos Periféricos/crescimento & desenvolvimento , Alcamidas Poli-Insaturadas/metabolismo , Medula Espinal/efeitos dos fármacos , Medula Espinal/crescimento & desenvolvimento , Medula Espinal/metabolismo , Estereoisomerismo
18.
J Microencapsul ; 30(7): 674-80, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23444868

RESUMO

A unique flurbiprofen-loaded nanoemulsion was listed earlier using a Shirasu porous glass (SPG) membrane emulsification technique, which gave constant emulsion droplets with a thin size distribution. In this study, a flurbiprofen-loaded nanoemulsion was developed further into a solid form using polyvinylpyrrolidone (PVP) as a carrier by a spray-drying technique. The flurbiprofen-loaded nanoparticles with a weight ratio of flurbiprofen/PVP/surfactant mixture of 1/8/2 were connected with about 130,000-fold enhanced drug solubility and had a mean size of about 70 nm. In these nanoparticles, flurbiprofen was found in an altered amorphous state. Additionally, the nanoparticles gave significantly shorter T(max), and greater AUC and C(max) compared to the commercially available product. Specially, the AUC of the drug from the nanoparticles was about 10-fold greater compared to the commercially available product. Therefore, these flurbiprofen-loaded nanoparticles can be convenient for distributing a poorly water-soluble flurbiprofen with improved bioavailability using uniform nano-sized particles.


Assuntos
Analgésicos/administração & dosagem , Anti-Inflamatórios não Esteroides/administração & dosagem , Portadores de Fármacos/química , Flurbiprofeno/administração & dosagem , Nanopartículas/química , Povidona/química , Analgésicos/sangue , Animais , Anti-Inflamatórios não Esteroides/sangue , Dessecação , Emulsões/química , Flurbiprofeno/sangue , Masculino , Tamanho da Partícula , Porosidade , Ratos , Ratos Sprague-Dawley
19.
Alzheimer Dis Assoc Disord ; 27(3): 278-86, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-22922591

RESUMO

CHF5074 has been shown to inhibit brain ß-amyloid deposition and attenuate memory deficits in different transgenic mice models of Alzheimer disease. We evaluated the safety, pharmacokinetics, and pharmacodynamics of 3 ascending dose regimens of CHF5074 (200, 400, and 600 mg/d for 14 d) in a double-blind, placebo-controlled, parallel group study involving 48 healthy subjects. Plasma, urine, and cerebrospinal fluid (CSF) samples were collected for measuring drug and main metabolite concentrations and potential biomarkers of pharmacodynamic activity (ß-amyloid1-40, ß-amyloid1-42, soluble CD40 ligand, and tumor necrosis factor-α). All subjects completed the study, and no serious or severe adverse events were reported. The maximum tolerated dose was close to 600 mg/d with mild diarrhea being the most frequent adverse event at this dose. CHF5074 reached peak plasma levels 2 to 3 hours after drug administration and then was slowly eliminated (t(1/2z)=30 h) in the urine as glucoronide. Systemic exposure to the drug appeared to be dose-proportional with a 2-fold accumulation ratio at steady state. Metabolite plasma levels peaked at 4 to 5 hours and accounted for about 25% of the parent compound. Drug levels in the CSF were dose-proportional. The drug dose-dependently lowered the levels of the soluble CD40 ligand, a marker of microglia activation, in both plasma and CSF samples.


Assuntos
Ciclopropanos/farmacocinética , Flurbiprofeno/análogos & derivados , Fármacos Neuroprotetores/farmacocinética , Adulto , Ciclopropanos/efeitos adversos , Ciclopropanos/sangue , Relação Dose-Resposta a Droga , Método Duplo-Cego , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/sangue , Inibidores Enzimáticos/farmacocinética , Flurbiprofeno/efeitos adversos , Flurbiprofeno/sangue , Flurbiprofeno/farmacocinética , Humanos , Masculino , Dose Máxima Tolerável , Pessoa de Meia-Idade , Fármacos Neuroprotetores/efeitos adversos , Fármacos Neuroprotetores/sangue , Adulto Jovem
20.
Xenobiotica ; 43(3): 246-52, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22867272

RESUMO

Adjuvant-induced arthritis (AA) in the rat is used as a model for rheumatoid arthritis. In AA rats, the pharmacokinetics of various drugs is affected due to the alterations of plasma protein binding of drugs. We choose propranolol (PL) and flurbiprofen (FP) as model basic and acidic drugs, respectively, and investigated the effect of AA induction on their plasma protein binding at each developing stage of inflammation. The plasma protein binding of PL and FP was dramatically changed due to reduced albumin and increased α1-acid glycoprotein levels for at least 21 days after adjuvant treatment. Moreover, we illustrated the differences in protein binding in AA between both the drugs in each developing stage of inflammation. These results suggest that the changed plasma protein levels in AA rats accompanying the altered protein binding of drugs affect the pharmacokinetics of drugs which extensively bind to plasma protein under inflammatory condition.


Assuntos
Artrite Experimental/sangue , Artrite Experimental/patologia , Proteínas Sanguíneas/metabolismo , Flurbiprofeno/metabolismo , Propranolol/metabolismo , Fosfatase Alcalina/sangue , Animais , Aspartato Aminotransferases/sangue , Feminino , Flurbiprofeno/sangue , L-Lactato Desidrogenase/sangue , Orosomucoide/metabolismo , Propranolol/sangue , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Albumina Sérica/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...